Zealand, Boehringer receive FDA breakthrough status for treatment of fatty liver dystrophy

Danish Zealand Pharma and German partner Boehringer Ingelheim have won the US Food and Drug Administration’s Breakthrough Therapy competition to review their experimental weight-loss drug for the treatment of fatty liver disease.

Compartir esta publicacion:

ENTRADAS POPULARES
SÍGANOS
Danos like en facebook
Síganos en Twitter
Suscríbase a nuestro canal
Tik Tok
TRANSMISIÓN EN VIVO